Avacta’s Chief Scientific Officer to Present Therapeutics Update at PEGS Europe

Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, is pleased to announce that its Chief Scientific Officer, Dr Amrik Basran, will be presenting an update on the Affimer therapeutics programmes at the Protein and Antibody Engineering Summit, 13-17 November 2017 in Lisbon, Portugal.

Dr Basran will present recent progress in the Affimer therapeutic programmes and will focus on PD-L1 immune checkpoint inhibitors and half life extension methods.

Dr Basran will discuss new data concerning a range of Affimer proteins that bind to serum albumin, which can be used to form bispecifics to extend serum half-life.  A range of species specific (human, mouse, cynomolgus monkey and dog) albumin binders have been generated and data will be presented that show that these molecules significantly extend the serum half-life of the Affimer scaffold and therefore offer a valuable alternative to other methods for the creation of biotherapeutics with long serum half-life.